Maternal Respiratory Syncytial Virus (RSV) Vaccination: Current Status and Comparison to Monoclonal Antibodies (mAbs) for RSV Prevention in Infants and Children.

Journal of mother and child Pub Date : 2025-08-16 eCollection Date: 2025-02-01 DOI:10.34763/jmotherandchild.20252901.d-25-00012

Ahila Ali, Laiba Shamim, Ahmed Ibrahim, Muhammad Abdullah Humayun, Muhammad Hamza Khan, Anum Akbar, Sanmit Jindal, Shahzaib Ahmed, Jamuna Shrestha, Muhammad Abdullah Nveed

{"title":"Maternal Respiratory Syncytial Virus (RSV) Vaccination: Current Status and Comparison to Monoclonal Antibodies (mAbs) for RSV Prevention in Infants and Children.","authors":"Ahila Ali, Laiba Shamim, Ahmed Ibrahim, Muhammad Abdullah Humayun, Muhammad Hamza Khan, Anum Akbar, Sanmit Jindal, Shahzaib Ahmed, Jamuna Shrestha, Muhammad Abdullah Nveed","doi":"10.34763/jmotherandchild.20252901.d-25-00012","DOIUrl":null,"url":null,"abstract":"<p><p>Respiratory Syncytial Virus (RSV) causes over 50,000 hospitalizations annually among children under five years of age, leading to long-term consequences, such as asthma. Monoclonal antibodies (mAb) have been recommended for prevention, but their limitations have prompted the search for alternative preventive measures. The recent Food and Drug Administration (FDA) approval of a maternal RSV vaccine with 80% efficacy in protecting infants up to 90 days post-birth marks a significant advancement. Our narrative review investigates the differences in RSV immunization in pregnant mothers versus infants and children, with the goal of identifying factors that influence parental decisions. This study provides insights for optimising preventive strategies, and the results highlight the importance of maternal vaccination in combating RSV in children.</p>","PeriodicalId":73842,"journal":{"name":"Journal of mother and child","volume":"29 1","pages":"93-100"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12359126/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of mother and child","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34763/jmotherandchild.20252901.d-25-00012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Respiratory Syncytial Virus (RSV) causes over 50,000 hospitalizations annually among children under five years of age, leading to long-term consequences, such as asthma. Monoclonal antibodies (mAb) have been recommended for prevention, but their limitations have prompted the search for alternative preventive measures. The recent Food and Drug Administration (FDA) approval of a maternal RSV vaccine with 80% efficacy in protecting infants up to 90 days post-birth marks a significant advancement. Our narrative review investigates the differences in RSV immunization in pregnant mothers versus infants and children, with the goal of identifying factors that influence parental decisions. This study provides insights for optimising preventive strategies, and the results highlight the importance of maternal vaccination in combating RSV in children.

Abstract Image

查看原文本刊更多论文

母亲呼吸道合胞病毒（RSV）疫苗接种现状及单克隆抗体（mab）预防婴儿和儿童RSV的比较

呼吸道合胞病毒（RSV）每年导致5万多名5岁以下儿童住院，导致哮喘等长期后果。单克隆抗体（mAb）已被推荐用于预防，但其局限性促使人们寻找替代的预防措施。最近，美国食品和药物管理局（FDA）批准了一种母亲RSV疫苗，该疫苗对出生后90天内的婴儿具有80%的保护功效，这标志着一项重大进展。我们的叙述性综述调查了孕妇与婴儿和儿童在RSV免疫方面的差异，目的是确定影响父母决定的因素。这项研究为优化预防策略提供了见解，结果强调了母亲接种疫苗在对抗儿童呼吸道合胞病毒中的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of mother and child

CiteScore

1.30

自引率

0.00%

发文量